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Background: The purpose of this study was to assess the safety and efficacy of oral 
glycopyrrolate solution 1 mg/5 mL for 24 weeks in pediatric patients with chronic moderate-
to-severe drooling associated with cerebral palsy and other neurologic conditions.
Methods: In this multicenter, open-label, 24-week study, males and females aged 3–18 years 
weighing at least 27 lb received oral glycopyrrolate solution, starting at 0.02 mg/kg three 
times daily and titrated in increments of 0.02 mg/kg every 5–7 days for 4 weeks to an optimal 
maintenance dose or a maximum dose of 0.1 mg/kg, but not exceeding 3 mg three times daily. 
Safety was assessed by description and tabulation of all adverse events. The primary efficacy 
endpoint was response, defined as at least a three-point change from baseline to week 24 on the 
modified Teacher’s Drooling Scale.
Results: Of 137 intent-to-treat participants, 10 (7.3%) received the maximum dose of 0.1 mg/kg 
three times daily; 122 (89%) had at least one treatment-emergent adverse event, 47% related 
to oral glycopyrrolate solution, with most being mild-to-moderate in intensity. The most 
commonly reported treatment-emergent adverse events were constipation (20.4%),   vomiting 
(17.5%), diarrhea (17.5%), pyrexia (14.6%), dry mouth (10.9%), flushing (10.9%), and nasal 
congestion (10.9%). Nineteen patients (13.9%) discontinued treatment due to an adverse 
event, but no adverse event was specifically associated with discontinuation. Two patients had 
  clinically significant toxicity grade shifts, one each in platelet count and calcium concentration. 
No deaths occurred on treatment; deaths of three patients (multisystem organ failure, anoxic 
encephalopathy, and aspiration pneumonia) within 30 days of their last dose were not considered 
to be treatment-related. At 24 weeks, 52.3% (95% confidence interval 43.7–60.9) of patients 
were responders, with at least a three-point decrease in modified Teacher’s Drooling Scale from 
baseline, with 83.5% of parents/caregivers and 85.8% of investigators rating oral glycopyrrolate 
solution as being worthwhile.
Conclusion: Oral glycopyrrolate solution 1 mg/5 mL for chronic moderate-to-severe drooling 
associated with cerebral palsy or other neurologic conditions was well tolerated over 24 weeks 
by pediatric patients aged 3–18 years.
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Introduction
An estimated 10%–37% of developmentally disabled individuals have moderate-
to-severe sialorrhea.1–3 In children with cerebral palsy and other neuromuscular 
conditions, drooling is primarily due to oral motor dysfunction.4,5 Glycopyrrolate 
(glycopyrronium bromide), a synthetic quaternary ammonium anticholinergic agent,6 Therapeutics and Clinical Risk Management 2012:8 submit your manuscript | www.dovepress.com
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was first approved for clinical use in 1961. Indications 
include adjunctive treatment of peptic ulcer disease in adults, 
preoperative or intraoperative inhibition of salivation and 
excessive respiratory tract secretions in adults and children 
aged $2 years, and management of secretions in children 
with tracheostomies.7,8 Glycopyrrolate penetrates the blood–
brain barrier poorly, and therefore has reduced potential to 
cause central nervous system effects.9,10
Although off-label use of glycopyrrolate tablets has been 
shown to decrease drooling in children with cerebral palsy,11–14 
these tablets require compounding to treat pediatric patients. 
The highly variable pharmacokinetics of this formulation of 
glycopyrrolate can result in wide-ranging effective doses and 
cause adverse events that lead to treatment discontinuation.14 
For example, a placebo-controlled trial in 39 children found 
that the mean highest tolerated dose of glycopyrrolate was 
2.49 mg (0.11 mg/kg), ranging from 1.2 mg (0.04 mg/kg) to 
3.0 mg (0.2 mg/kg), with most children showing improvement 
in drooling at doses of 0.1 mg/kg.14 These findings suggest that 
the initial dose should be 0.04 mg/kg, followed by stepwise 
increases to an effective dose that can be tolerated without 
significant adverse events.14 Results from a retrospective trial 
in 37 patients found that the mean dose of glycopyrrolate was 
0.51 mg/kg, with 86% of patients receiving 0.02–0.07 mg/kg 
doses.15 In an open-label trial, 24 patients were treated with 
0.04–0.10 mg/kg glycopyrrolate once daily, with patients 
started on lower doses and titrated until drooling significantly 
decreased or stopped.12 In another open-label trial, 40 patients 
were treated with 0.5 mg glycopyrrolate once or twice daily.11 
Effective doses ranged from 0.01–0.82 mg/kg/day (1.0–8.0 mg/
day; median, 0.09 mg/kg/day), with glycopyrrolate adminis-
tered 1–5 times per day.11
To provide more accurate pediatric dosing and titration, a 
novel liquid formulation of glycopyrrolate was developed at 
a concentration of 1.0 mg/5 mL. Glycopyrrolate was started 
at a dose of 0.2 mg/kg three times daily, with dose increases 
to 0.04, 0.06, 0.08, and 0.10 mg/kg. This open-label trial 
assessed the 24-week safety of oral glycopyrrolate solution 
(1 mg/5 mL) in pediatric patients aged 3–18 years with 
chronic, moderate-to-severe drooling associated with cerebral 
palsy and other neurologic conditions. We also assessed the 
efficacy of maintenance doses of glycopyrrolate oral solution 
in managing drooling in this patient population.
Materials and methods
Patient selection
We enrolled male and female patients aged 3–18 years and 
weighing at least 12.3 kg, who had been diagnosed with 
cerebral palsy, mental retardation, or any other neurologic 
impairment or condition with chronic drooling, defined as 
wetness of the chin or clothing on most days. All patients 
had scores $5 on the nine-point modified Teacher’s Drooling 
Scale (mTDS, Table 1). Both cognitively capable and 
cognitively impaired patients were eligible.
All patients lived in a situation where reliable parents/
caregivers were willing and capable of administering medi-
cations, as determined by the investigator. Written informed 
consent, signed by the parent or legally acceptable representa-
tive, and written assent, signed by age-appropriate patients if 
mentally capable, were required for participation. Females of 
childbearing potential had to have negative pregnancy tests at 
screening and at week 8. Sexually active females had to agree 
to use a medically acceptable form of contraception.
The study protocol was approved by the institutional 
review board of each participating institution, and each 
patient or the patient’s parent/legal guardian provided 
  written informed consent, in accordance with Good 
Clinical Practice guidelines, the current version of the 
Declaration of   Helsinki, and the United States Food and 
Drug Administration Regulations Title 21 code of Federal 
  Regulations Parts 50.20–50.27.
Patients were excluded prior to baseline (day -2) if they 
had used or received glycopyrrolate (within approximately 
24 hours), prohibited medications (within five plasma half-
lives of the medication), intrasalivary gland botulinum 
toxin (within 10 months), intraoral devices or prosthetics 
for treatment of drooling (within one week), or acupuncture 
for the treatment of drooling (within 3 months). We also 
excluded patients with medical conditions contraindicating 
anticholinergic therapy, known contraindications to the study 
medication, poorly controlled seizures (defined as daily 
seizures), a history of intestinal obstruction, or clinically 
significant hepatic or renal impairment, as well as pregnant 
or breastfeeding females and any patient who had received 
any investigational drug within 30 days of study entry. In 
addition, the investigator could exclude patients and   families 
Table 1 Modified Teacher’s Drooling Scale
1 = Dry: never drools
2 = Mild: only the lips are wet; occasionally
3 = Mild: only the lips are wet; frequently
4 = Moderate: wet on the lips and chin; occasionally
5 = Moderate: wet on the lips and chin; frequently
6 = severe: drools to the extent that clothing becomes damp; occasionally
7 = severe: drools to the extent that clothing becomes damp; frequently
8 = Profuse: clothing, hands, tray, and objects become wet; occasionally
9 = Profuse: clothing, hands, tray, and objects become wet; frequentlyTherapeutics and Clinical Risk Management 2012:8 submit your manuscript | www.dovepress.com
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or parents/caregivers expected to be noncompliant with 
study procedures, as well as patients unable to meet study 
requirements for any reason or those with unstable mental 
disease.
study design
The study was conducted at 28 sites in the United States. 
Patients were stratified according to whether they had or had 
not received glycopyrrolate for drooling within 3 months 
of initiating the study treatment. The treatment period was 
24 weeks, with scheduled visits on day 1 and at weeks 4, 8, 
12, 16, 20, and 24.
Treatments
After a washout, screening period, and a 2-day   baseline 
period, oral glycopyrrolate solution 1 mg/5 mL was 
titrated over 4 weeks in each patient. The starting dose 
was 0.02 mg/kg three times daily, followed by titration in 
  increments of 0.02 mg/kg every 5–7 days for 4 weeks to an 
optimal maintenance dose or a maximum dose of 0.1 mg/kg, 
but not exceeding 3 mg three times daily. The optimal dose 
was defined as the dose at which a patient received the 
maximum benefit from the study drug (greatest improvement 
in drooling) while experiencing minimum side effects, 
with increases and decreases in doses determined by the 
investigator in coordination with the parent/caregiver.
safety
Safety was assessed by description and tabulation of all 
adverse events. To help identify adverse events, a training 
manual was provided to the parent/caregiver which included 
information about the pharmacologic effects and adverse 
events associated with glycopyrrolate, as well as instructions 
on how to measure and administer the drug. This manual 
was provided to the parent/caregiver at visit 1 for mandatory 
reading and reviewed with qualified study personnel at visit 
2 with regard to each parent/caregiver’s understanding of 
dose measurement, three times daily dosing schedule, dose 
titration process, and potential adverse events associated with 
glycopyrrolate. The modified Behavioral and Medical Rating 
Scale (mBMRS) was completed by the parent/caregiver twice 
weekly (every 3–4 days) from the first dose of study drug until 
week 4, then once weekly for the remainder of the study. The 
mBMRS includes 28 predefined symptoms, each rated on a 
four-point scale, ie, 1 = not at all, 2 = just a little, 3 = quite a 
bit, and 4 = very much (Table 2). Behavioral, physiological, 
and total symptom scores were calculated at each visit, 
with a positive change indicating symptom improvement. 
Safety was also assessed by physical examination; a 12-lead 
electrocardiogram at screening and weeks 4, 12 and 24; 
clinical laboratory evaluation (blood chemistry, hematology, 
and urinalysis); and measurement of vital signs (heart rate, 
respiratory rate, systolic and diastolic blood pressure, and 
temperature). Hematology, gastrointestinal, and renal and 
electrolyte clinical laboratory results that worsened more than 
one toxicity grade from baseline were considered clinically 
significant.
Efficacy
The primary efficacy endpoint was change from baseline 
to week 24 on the mTDS, as determined by the parent/
caregiver. Patients showing at least a three-point decrease 
on the mTDS were defined as responders, whereas those 
showing a less than three-point decrease were defined as 
nonresponders. Secondary efficacy endpoints included 
parent/caregiver assessment of extent of drooling on the 
day for each applicable visit, as determined on a visual 
analog scale, and investigator and parent/caregiver global 
assessment of treatment, as determined by responses to the 
statement, “This is a worthwhile treatment,” using a five-
point scale, ie, strongly agree, agree, neutral, disagree, or 
strongly disagree.
statistical methods
Safety analysis included a descriptive tabulation of adverse 
events, listed in order of decreasing frequency. No statistical 
Table 2 Prespecified behavioral and physiological symptoms in 
the modified Behavioral and Medical Rating Scale
Behavioral Physiological
Restless/overactive Fearful
excitable/impulsive Diarrhea
Disturbs other children Constipation
Fails to finish things he or she starts/ 
short attention span
Drowsy
Constantly fidgeting nasal congestion
inattentive/easily distracted Vomiting
Demands must be met immediately/ 
easily frustrated
irritable
Cries often and easily Dry mouth
Mood changes quickly and drastically Difficulty urinating
Temper outbursts/explosive and  
unpredictable behavior
Flushing of skin  
on face or body
Overly serious, sad, or sensitive headache
Change in coordination and/or body control Blurred vision
heart palpitations
increased heart rate
skin rash
skin hivesTherapeutics and Clinical Risk Management 2012:8 submit your manuscript | www.dovepress.com
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hypothesis testing was performed for the safety analysis. 
Visual analog scores and Global Assessment of Treatment 
were summarized using descriptive statistics for continuous 
variables and frequency and percentage for discrete vari-
ables. Laboratory values were summarized and change from 
screening determined. The primary efficacy analysis used the 
mean of each daily postdose evaluation (ie, calculation of the 
mean of three postdose evaluations for each day). Patients 
were   classified as responders if they had at least a three-point 
decrease in mean mTDS from baseline to week 24, otherwise 
as nonresponders.
Results
This study was performed between April 2007 and May 2008. 
Of the 160 patients enrolled, 23 were deemed screen failures 
and did not receive study drug, although one patient who 
was recorded as a screen failure received study drug and 
was included in the intent-to-treat population. The baseline 
characteristics of the 137 who received at least one dose of 
study drug are summarized in Table 3 and are included in the 
analysis. Of these 137 patients, 103 (75.2%) completed the 
study; of the 34 patients (24.8%) who discontinued early, two 
did so due to lack of efficacy and 14 due to adverse events. 
Other reasons for discontinuation included failure to meet 
entry criteria (n = 2), investigator decision (n = 2), patient 
noncompliance (n = 2), patient/parent decision (n = 5), loss 
to follow-up (n = 3), death (n = 3; see Safety section), and 
other (n = 1).
Overall extent of exposure
The mean daily dose of oral glycopyrrolate solution was 
0.15 mg/kg, with 70 of the 137 patients (51.1%) receiv-
ing a mean daily dose of $0.1 mg/kg to #0.2 mg/kg, and 
10 (7.3%) receiving the maximum dose of 0.1 mg three times 
daily. Doses were reduced in about 45% of patients over 
the 24-week study period. Patients were treated for a mean 
139.8 days, with 104 patients (75.9%) treated for .150 days 
to #200 days.
safety
Most patients (n = 122; 89%) had at least one treatment-
  emergent adverse event, 47% of which were deemed 
related to oral glycopyrrolate solution, with most being 
mild-to-  moderate in intensity. The most commonly reported 
treatment-emergent adverse events are   summarized in 
Table 4. Several treatment-emergent adverse events 
occurred more frequently in the high-dose (.0.2 mg/kg) 
and middle-dose ($0.1 to #0.2 mg/kg) than in the low-dose 
(,0.1 mg/kg) group, including vomiting (18.4% versus 
18.6% versus 13.8%), dry mouth (15.8% versus 11.4% versus 
3.4%), otitis media (10.5% versus 10.0% versus 3.4%), upper 
respiratory tract infection (7.9% versus 10.0% versus 3.4%), 
pneumonia (7.9% versus 5.7% versus 0%), streptococcal 
pharyngitis (7.9% versus 4.3% versus 3.4%), epistaxis (7.9% 
versus 4.3% versus 3.4%), somnolence (2.6% versus 8.6% 
versus 0%), pyrexia (18.4% versus 15.7% versus 6.9%), and 
rash (5.3% versus 11.4% versus 3.4%). Fourteen patients had 
20 serious adverse events, eight while taking the study drug 
and six within 30 days of the last dose. Of these 20 serious 
Table 3 Baseline characteristics of the intent-to-treat population 
(n = 137)
Baseline characteristics Glycopyrrolate oral 
solution 1 mg/5 mL
Age (years), mean (standard deviation) 11.0 (4.4)
gender
  Male 77 (56.2%)
  Female 60 (43.8%)
Race
  White 98 (71.5%)
  Black or African-American 29 (21.2%)
  Other 10 (7.3%)
ethnicity
  hispanic or Latino 15 (11.0%)
  not hispanic or Latino 121 (89.0%)
  Missing 1
history of glycopyrrolate use
  Yes 53 (38.7%)
  no 84 (61.3%)
Tracheostomy
  Yes 16 (11.7%)
  no 121 (88.3%)
Uses tube for feeding
  Yes 70 (51.1%)
  no 67 (48.9%)
Patient has cerebral palsy
  Yes 96 (70.1%)
  no 41 (29.9%)
Cerebral palsy category 1
  spastic 78 (81.3%)
  hypotonic 8 (8.3%)
  Ataxic 2 (2.1%)
  Athetoid 3 (3.1%)
  Mixed 5 (5.2%)
  Missing 41
Cerebral palsy category 2
  Quadriplegic 79 (83.2%)
  hemiplegic 6 (6.3%)
  Diplegic 7 (7.4%)
  Triplegic 3 (3.2%)
  Missing 42
Residence of patient
  At home with parent 91 (66.4%)
  At home with foster parent/guardian 12 (8.8%)
  institutional setting 34 (24.8%)Therapeutics and Clinical Risk Management 2012:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
29
glycopyrrolate solution for drooling in children
adverse events, four were considered treatment-related, ie, 
nystagmus, esophageal candidiasis, dehydration, and gastro-
intestinal motility disorder. Nineteen patients discontinued 
due to an adverse event, including the 14 patients who termi-
nated participation due to an adverse event associated with 
the study drug, three patients who died of an adverse event 
not associated with the study drug, and two who withdrew 
consent to participate. However, there was no obvious trend 
in type of event that led to discontinuation.
Generally, adverse event rates were slightly higher in the 
84 patients naïve to treatment with oral glycopyrrolate solu-
tion than in the 53 patients previously treated with this drug. 
These included rates of treatment-emergent adverse events 
(90.5% versus 86.8%), drug-related treatment-emergent 
adverse events (50.0% versus 41.5%), severe treatment-
emergent adverse events (9.5% versus 5.7%), serious adverse 
events (11.9% versus 7.5%), deaths (2.4% versus 1.9%) and 
adverse events resulting in discontinuation of study (14.3% 
versus 3.8%). In contrast, naïve patients had lower rates of 
serious treatment-emergent adverse events than non-naïve 
patients (4.8% versus 7.5%).
The mBMRS, intended to help the parent/caregiver 
identify possible adverse event-related behaviors and 
physiological effects in patients taking oral glycopyrrolate 
solution, enabled the identification of 24.7% of adverse 
events by parents/caregivers and 1.8% by investigators. 
Clinically significant toxicity grade shifts, from grade 0 
at baseline to grade 2 at week 24/exit visit, were observed 
in two patients, one in platelet count (from 3.9 × 105/µL 
at baseline to 6.7 × 104/µL at week 24/exit visit) and one 
in calcium concentration (from 9.2 mg/dL at baseline to 
7.2 mg/dL at week 24/exit visit). No deaths were reported 
while patients were on oral glycopyrrolate solution. Three 
deaths occurred within 30 days of the last dose, one each due 
to multisystem organ failure, anoxic encephalopathy, and 
aspiration pneumonia, but none was considered treatment-
related by the investigators.
There were no notable changes in mean hematology 
or chemistry parameters. Hematology parameters were 
measured in 65% and 79% of patients at baseline and 
week 24, respectively. Decreases .10% from the normal 
reference range at baseline to below that range at week 24 
were observed for absolute neutrophil (11.2%) and red blood 
cell (11.1%) count, and increases .10% from the normal 
reference range at baseline to above that at week 24 were 
observed for monocyte (16.7%) and absolute monocyte 
(11.2%) counts. Chemistry parameters were measured in 
68% and 82% of patients at baseline and the final visit, 
respectively, except for bicarbonate, which was measured 
in only 15 patients at both time points. Decreases .10% 
from the normal reference range at baseline to below 
that range at week 24 were observed for carbon dioxide 
(15.1%), bicarbonate (13.3%), and creatinine (10.7%) 
concentrations, but there were no increases .10% from 
the normal reference range at baseline to above that range 
at week 24.
Although there were minor fluctuations in vital signs, 
including mean systolic and diastolic blood pressure, pulse 
rate, respiration rate, temperature, and weight, over the course 
of the study, none of these changes was clinically notable. 
Shifts from normal at baseline to abnormal and clinically 
significant at week 24 in .1% of patients who underwent 
physical examinations at both visits were observed in the 
extremities (3.2%), head, ears, eyes, nose, and throat (1.6%), 
and in psychology (1.6%).
Electrocardiographic interval durations were examined 
across six dose levels at weeks 4, 12, and 24 by both time 
averaged and per time point techniques. No abnormal or 
clinically significant shifts in electrocardiographic findings 
were observed in patients with electrocardiographic results 
at baseline and week 24. The electrocardiographic interval 
data showed that oral glycopyrrolate solution had no 
obvious effect on heart rate or atrioventricular conduction, 
as measured by PR interval, or depolarization, as measured 
by QRS duration. There was no evidence of any clinically 
relevant changes in QTc duration, or imbalances in specific 
and nonspecific outliers. Morphological changes were 
noted in T wave changes, which were likely spurious (not 
dose-related and of very low frequency). One patient had 
an abnormal, clinically significant electrocardiographic 
tracing during the study, indicating sinus tachycardia, 
incomplete right bundle branch block, and left atrial 
enlargement; this patient died of multiorgan failure before 
completing the study, but the death was deemed unrelated 
to the study drug by the investigator.
Table 4 Most frequently observed (.5%) treatment-emergent 
adverse events (n = 137)
Adverse event Oral glycopyrrolate solution   
1 mg/5 mL
Constipation 28 (20.4%)
Vomiting 24 (17.5%)
Diarrhea 24 (17.5%)
Pyrexia 20 (14.6%)
Dry mouth 15 (10.9%)
Flushing 15 (10.9%)
nasal congestion 15 (10.9%)Therapeutics and Clinical Risk Management 2012:8 submit your manuscript | www.dovepress.com
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Efficacy
At the week 24/exit visit, 52.3% (95% confidence interval 
[CI] 43.7–60.9) of patients had an at least three-point decrease 
in mTDS from baseline and were classified as responders to 
treatment with oral glycopyrrolate solution. The proportion 
of responders from week 4 (visit 1) to week 24 (exit visit) 
is shown in Figure 1. The percentage of the 53 non-naïve 
patients (ie, patients previously treated with glycopyrrolate) 
classified as responders (58.5%; 95% CI 45.2–71.8) was 
higher than that of the 84 naïve patients (48.1%; 95% 
CI 36.9–59.2). The percentages of patients with profuse, 
severe, and moderate drooling decreased substantially after 
24 weeks of treatment, from 31.6% to 2.3%, from 36.6% to 
8.3%, and from 32.1% to 25.6%, respectively. At the end of 
the study, 15% of patients no longer drooled. The percentages 
of responders by dose group are summarized in Table 5.
Improvements in the extent of drooling were also 
observed using the visual analog scale assessment. The 
mean visual analog score was reduced from 6.56 at base-
line to 3.21 at 24 weeks. These scores were similar in 
glycopyrrolate-naïve and glycopyrrolate-non-naïve patients. 
At the end of the study, 83.5% of parents/caregivers and 
85.8% of investigators rated oral glycopyrrolate solution as 
a worthwhile treatment.
Discussion
This study demonstrated that 24 weeks of treatment with 
oral glycopyrrolate solution 1 mg/5 mL for chronic, 
  moderate-to-severe drooling associated with cerebral 
palsy and other neurologic conditions was well tolerated 
by children 3–18 years of age. More than 80% of patients 
had cerebral palsy classified as spastic or quadriplegic; 
.90% were developmentally disabled and had impaired 
speech, approximately 75% resided at home with a 
parent or a foster parent or guardian, and .60% were 
glycopyrrolate-naïve.
The treatment-emergent adverse events observed in 
these patients were similar to those in patients treated with 
glycopyrrolate tablets.11–14 Clinical trials of glycopyrrolate 
tablets to manage drooling in patients with cerebral palsy 
and other neurodevelopmental conditions have reported 
behavioral changes (including hyperactivity and irritability), 
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Figure 1 Proportion of responders after 4–24 weeks of treatment with oral glycopyrrolate solution 1 mg/5 mL. Response was defined as at least a three-point decrease on 
the Modified Teachers’ Drooling Scale. The percentage of responders at each time point from week 4 to week 20 was assessed relative to the number of patients remaining 
on study at that time point. The percentage of responders at week 24 was assessed relative to all intent-to-treat patients (n = 137), except for seven patients with missing 
values. Patients who discontinued treatment due to lack of efficacy had their worst observation carried forward, whereas patients who discontinued due to any other reason 
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constipation, diarrhea, excessive oral dryness, urinary 
retention, headache, drowsiness, dilated pupils, blurred 
vision, facial flushing, nasal congestion, vomiting, dizzi-
ness, dehydration, fever, and rash.11–14 No unexpected safety 
issues were identified in 24 weeks of treatment with oral 
glycopyrrolate solution.
The primary adverse event observed with oral glycopyr-
rolate solution was constipation; other adverse events were 
related to its mechanism of action as an anticholinergic. The 
increase in adverse events observed with higher doses of 
oral glycopyrrolate solution was similar to that in a study of 
glycopyrrolate tablets in developmentally disabled children 
with sialorrhea, which attempted to identify the dose at which 
the curve of reduced drooling crossed the curve of increased 
adverse effects.14 Adverse events increased as the dose 
increased; 20% of children stopped taking glycopyrrolate 
due to adverse events, the most frequent being behavioral 
problems, constipation, excessive oral dryness, and urinary 
retention.14
Although the overall incidence of abnormal laboratory 
test results in this study was low, two patients had clini-
cally significant toxicity grade shifts in laboratory values. 
No clinically notable changes in vital signs were observed. 
Although the low frequency of electrocardiograms, the lack 
of a placebo control, and the small overall sample size limit 
the interpretability of our electrocardiographic results, we 
did not observe any notable electrocardiographic changes 
associated with treatment with oral glycopyrrolate solution. 
Moreover, to our knowledge, no association has been reported 
between glycopyrrolate treatment and torsade de pointes or 
QT prolongation.
We found that the percentage of patients with profuse, 
severe, or moderate drooling was markedly reduced after 
24 weeks of treatment with oral glycopyrrolate solution. 
Improvements in the extent of drooling were also observed 
using the visual analog scale assessment. Most parents/
caregivers and investigators rated oral glycopyrrolate solu-
tion as a worthwhile treatment.
Results of a randomized, placebo-controlled efficacy 
trial16 and this study led to approval by the US Food and 
Drug Administration in July 2010 of oral glycopyrrolate 
solution 1 mg/5 mL to reduce chronic severe drooling 
in patients aged 3–16 years with neurologic conditions 
associated with problem drooling (eg, cerebral palsy).17 
The liquid formulation provides for consistent and reliable 
dose adjustments based on individual patient response to 
treatment and permits more precise weight-based dosing than 
is possible with oral tablets. Once an initial dose has been 
selected, clinical signs can be used to titrate the dose of oral 
glycopyrrolate solution for each child over several weeks 
until control of drooling is satisfactory, with maintenance 
dose individualized. Oral glycopyrrolate solution is 
contraindicated in patients with conditions that preclude 
anticholinergic therapy (eg, glaucoma, paralytic ileus, 
unstable cardiovascular status in acute hemorrhage, severe 
ulcerative colitis, toxic megacolon complicating ulcerative 
colitis, myasthenia gravis), in those taking solid oral forms 
of potassium chloride, and in those with constipation or 
intestinal pseudo-obstruction.17
Conclusion
Treatment for 24 weeks with oral glycopyrrolate solution 
1 mg/5 mL for the management of pathologic drooling associ-
ated with neurologic conditions was well tolerated by children 
aged 3–18 years. Oral glycopyrrolate solution substantially 
reduced the percentage of patients with profuse, severe, or 
moderate drooling.
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